Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
We recently published a list of Jim Cramer Discussed These 29 Stocks Ahead Of Major AI Event. In this article, we are going ...
She joins a team of experts at ON Partners, including partners Nina McMaster and Suzanne Zebedee, Ph.D., both recognized for ...
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...
This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback